David M. O’Malley
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute(US)The Ohio State University(US)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy, Intraperitoneal and Appendiceal Malignancies, Cancer Genomics and Diagnostics
Most-Cited Works
- → Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial(2017)1,842 cited
- → Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)1,678 cited
- → Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial(2016)1,190 cited
- → Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology(2021)695 cited
- → Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial(2017)594 cited